Hyperferritinemia can be the result of inflammation, infection, iron overload, or other uncommon pathologies including hemophagocytic lymphohistiocytosis (HLH). The significance of its elevation and its association with poor prognosis and critical clinical situations is unclear.
n INTRODUCTION F erritin is found in most tissues as a cytosolic protein and in small amounts secreted into the serum. It plays a key role in the storage of iron in soluble and nontoxic form and its release (1) . If ferritin is high, there is iron in excess or, alternatively, there is an acute inflammatory reaction in which ferritin is mobilized without iron excess. It can be elevated in multiple conditions including inflammation, infection and malignancy. The importance of this abnormal value is not well understood and its association with poor prognosis and critical clinical situations is unclear. Various studies suggested that markedly elevated ferritin in hospitalized patients is often associated with hemophagocytic lymphohistiocytosis syndrome (HLH) but cannot be considered as a specific marker (2, 3) . HLH syndrome is a rare diagnosis that is difficult to distinguish from other diseases because it has protean clinical, biological and histological presentation. The H score is a composite diagnostic score that estimates an individual's risk of having HLH (4). To understand the significance of elevated ferritin in hospitalized patients and to determine the underlying conditions, we performed a retrospective analysis of patients admitted to our hospital and found to have ferritin level above 2000 mg L -1 . Furthermore, we assessed retrospectively the diagnostic score for HLH for all patients to demonstrate the difficulties of managing situations that can mimic HLH clinically. Ferritin is an intracellular protein that stores iron. Plasma ferritin is an indirect marker of the total amount of iron stored in the body, hence serum ferritin is used as a diagnostic test. Elevated levels of ferritin indicate iron overload, but they are not specific as ferritin is an acute protein that increases in response to inflammatory states including malignancy, infection and in liver or renal diseases. Rheumatologists are often asked to manage patients with this condition because they are often thought to be exclusive. This situation is protean and its spectrum is wide. Previously published cohort studies choose 1000 mg L −1 as an appropriate cut off value for markedly elevated ferritin (2) . Other studies suggested that this level sets the threshold too low and that the sensitivity and specificity of ferritin for HLH should be raised to a cutoff level above 2000 mg L -1 (3) . This data is considered by other authors who used the same cut off level to 
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elaborate a diagnostic composite score for HLH called H score (4) . In our cohort, we considered this cut off to try to elaborate the etiological spectrum of patients with markedly elevated ferritin and estimate the probability of developing HLH. On the basis of our results in an inpatient setting, the most likely causes for an elevated ferritin are hematological malignancy, severe infection, iron overload, and chronic kidney disease. HLH was diagnosed in 14% of cases. These findings are different from literature data where liver injury and infections seems to be most predominant etiologies. This could be explained by recruitment bias. In fact, our center is a general hospital with local recruitment, compared to other cohorts from tertiary teaching hospitals or reference centers for oncology or liver disease. Nevertheless, we recorded more cases of HLH (3). In the subgroup of patients with ferritin above 6000 µgL -1 , we recorded 90% of our HLH patients, suggesting that a higher threshold of serum ferritin would be more specific of HLH. In this subgroup, however, we reported patients with hematological malignancy (35%) and sepsis (20%) as well. We conclude that high ferritin level cannot be used as a screening tool for HLH diagnosis and should be integrated into the clinical picture of HLH including fever, cytopenia, and organomegalia. We assessed the H score in all patients and showed that the probability of developing HLH was superior to 90% in 17.3% of cases. Thus, there were probably 2 HLH patients misdiagnosed in our cohort. We recommend the use of H score in each clinical situation with ferritin above 6000 µGl -1 to help physicians not misdiagnose HLH. Markedly elevated ferritin levels are far more likely to accompany non-rheumatologic diseases like infection, hematological malignancy and iron overload. This study demonstrated that high ferritin could be considered as a factor of poor prognosis and high level of mortality in patients with a level above 6000 mg L -1 . Further larger studies are certainly needed to confirm this finding. In accordance with previously published data, our findings support the fact that having high cut off value of ferritin, as used in the H score, may predict more patients with HLH diagnosis (3, 6) . The measurement can help support but not confirm this diagnosis. Despite the limitations inherent in a retrospective review, our cohort did not suffer from recruitment bias in comparison with those reported in tertiary academic hospitals where patients are referred for liver transplantation (2) . 
